Clinical Trials Browser

Phase 2 × Pathologic Complete Response × Bortezomib × Clear all

NCT00343720 2008-03-13

Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy

Phase 2 Completed

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis